Skip to main content
. Author manuscript; available in PMC: 2020 Sep 15.
Published in final edited form as: Clin Cancer Res. 2019 Dec 18;26(6):1309–1317. doi: 10.1158/1078-0432.CCR-19-2829

Figure 1: cfDNA 5-hmC profiles are associated with disease burden and disease status in both the Discovery and Validation cohorts.

Figure 1:

A) Hierarchical clustering of the Discovery cohort using 347 genes identified in the Discovery cohort with differential 5-hmC between samples from those with or without active disease. B) Hierarchical clustering of the Validation cohort using the same gene set and clustering parameters. Cluster 1 is enriched for patients with high metastatic disease burden. Clusters 2 and 3 are enriched for patients with moderate to high metastatic disease burden. Cluster 4 is enriched for patients with low or no metastatic disease burden.